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ABSTRACT
Objectives: To evaluate the effectiveness of adalimumab
in patients with psoriatic arthritis (PsA) and identify
predictors of good clinical response for joint and skin
lesions.
Methods: Patients received adalimumab 40 mg every
other week in addition to standard therapy in this
prospective, 12-week, open-label, uncontrolled study.
Four definitions of good clinical response were used:
>50% improvement in American College of
Rheumatology response criteria (ACR50), good response
according to European League Against Rheumatism
(EULAR) guidelines, a >3-grade improvement in Physician
Global Assessment of psoriasis (PGA) and a >50%
improvement in the Nail Psoriasis Severity Index (NAPSI).
Response predictors were determined by logistic regres-
sion with backward elimination (selection level was 5%).
Results: Of 442 patients, 94% completed 12 weeks of
treatment. At week 12, 74%, 51% and 32% of the
patients had achieved ACR20, 50 and 70, respectively;
87% and 61% experienced moderate and good responses
according to EULAR criteria, respectively. The percentage
of patients with PGA results of ‘‘clear/almost clear’’
increased from 34% (baseline) to 68%. The mean NAPSI
score was reduced by 44%. No new safety signals were
detected. A lower Health Assessment Questionnaire
Disability Index (HAQ-DI) score, greater pain assessment,
male sex and absence of systemic glucocorticoid therapy
were strongly associated with achievement of ACR50 and
good response according to EULAR criteria. In addition,
greater C-reactive protein concentration and polyarthritis
predicted ACR50, and non-involvement of large joints
predicted a good response according to EULAR criteria.
Conclusions: Adalimumab was effective in patients with
PsA. Lower impairment of physical function, greater pain,
male sex and no systemic treatment with glucocorticoids
were factors that increased the chance of achieving a
good clinical response.
Few studies have addressed whether predictors for
a good clinical response to treatment with tumour
necrosis factor (TNF) antagonists in patients with
psoriatic arthritis (PsA) can be identified. The
STEREO (for ‘‘SafeTy and Efficacy of adalimumab
in patients with active psoriatic arthritis – an open-
label, multinational study to evaluate the Response
to Every-Other week adalimumab when added to
insufficient standard therapy including patients
who failed prior treatment with other TNF
inhibitors’’) trial prospectively evaluated the treat-
ment effect of adalimumab in .400 patients with
active PsA who were eligible for treatment with
TNF antagonists in daily rheumatology practice.
12
We also evaluated predictive factors for a good
clinical response to adalimumab with respect to
arthritis, skin and nail disease.
METHODS
Patients
Main inclusion criteria were: age >18 years, PsA
diagnosed by a rheumatologist, >3 tender and >3
swollen joints, previous treatment with >1 dis-
ease-modifying antirheumatic drugs (DMARDs)
and enrolment in accordance with each participat-
ing country’s current guidelines for anti-TNF
treatment of PsA. DMARDs, non-steroidal anti-
inflammatory drugs (NSAIDs), or oral glucocorti-
coids ((10 mg prednisolone equivalent/day), as
well as topical psoriasis therapy, could be con-
tinued if the dosage was stable (additional details
regarding the inclusion/exclusion criteria and study
design are available in the supplementary mate-
rial).
Study design and measures
STEREO was a prospective, open-label, uncon-
trolled study conducted in nine European coun-
tries. Patients self-administered adalimumab 40 mg
(Abbott Laboratories, Abbott Park, Illinois, USA)
subcutaneously every other week for 12 weeks in
addition to their pre-existing antirheumatic treat-
ment. Patients who benefited from adalimumab
therapy could continue up to week 20 if adalimu-
mab was not commercially available. Observed
data at week 12 were used for all effectiveness
analyses. Presence or absence of dactylitis, defined
as swelling of the entire finger or toe, and
enthesitis at the heels were documented at base-
line. Measures of effectiveness for PsA were at least
20%, 50% and 70% improvements in the American
College of Rheumatology response criteria
(ACR20, ACR50 and ACR70, respectively),
3 tender
joint count (TJC; 0–78 joints), swollen joint count
(SJC; 0–76 joints), the 28-joint Disease Activity
Score (DAS28) based on erythrocyte sedimentation
rate (ESR; mm/first hour),
4 moderate and good
European League Against Rheumatism (EULAR)
response criteria using the DAS28,
5 and the PsA
response criteria (PsARC),
6 which was modified by
using a 0–100 mm visual analogue scale (VAS) for
the Physician or Patient Global Assessment of
disease activity (PhGA or PaGA). Additional
Extended report
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Assessment Questionnaire Disability Index (HAQ-DI; score of
0–3),
7 and C-reactive protein (CRP) concentration (mg/dl).
Psoriasis was assessed by Physician Global Assessment (PGA) for
psoriasis (a 7-point scale ranging from ‘‘clear’’ to ‘‘severe’’),
8
target lesion assessment (total plaque score 0–15, not assessed at
week 2) requiring a lesion of >2 cm in the greatest diameter at
baseline,
8 Nail Psoriasis Severity Index (NAPSI; 0–80, only of the
hands),
9 and the Dermatology Life Quality Index (DLQI; score
of 0–30).
10 NAPSI and DLQI were evaluated only at baseline,
week 12 and week 20.
Statistical analysis
All patients who received at least one adalimumab injection
were included in the analyses. Endpoints for good clinical
responses at week 12 were achievement of ACR50, a good
response according to EULAR criteria for PsA,
11 11 2improvement
by >3 grades in PGA for psoriasis (evaluated in patients with
PGA worse than ‘‘mild’’ at baseline) and a >50% improvement
in NAPSI score for psoriatic nail disorder (evaluated in patients
with NAPSI >10 at baseline).
Continuous variables analysed as possible predictors of good
clinical response for joint and skin/nail manifestations were age
(per year), duration of PsA (per year), CRP (per mg/dl), PhGA
and PaGA (per mm), pain (per mm); and DAS28 (per unit). In
addition, HAQ-DI score (per unit) was evaluated for PsA, and
duration of psoriasis (per year) and DLQI score (per unit) were
evaluated for skin and nail disorders.
Categorical variables (yes vs no) analysed as possible
predictors of good clinical response for joint and skin/nail
manifestations were: male sex; dactylitis; enthesitis; prior TNF
antagonist therapy; ongoing systemic treatment with >1
DMARDs, with sulfasalazine (SSZ), or with glucocorticoids;
history of tobacco use; >1 inflamed large joint (knee, shoulder,
elbow, hip); prior treatment with .2 DMARDs; polyarthritis
(>5 swollen joints) versus oligoarthritis (,5 swollen joints);
and PGA .‘‘moderate’’ versus PGA (‘‘moderate’’. For skin/nail
manifestations only, ongoing topical treatment with glucocor-
ticoids and prior ultraviolet A (UVA) and/or psoralen and UVA
(PUVA) phototherapy were evaluated.
Crude odds ratios (ORs) with 95% confidence intervals (CIs)
and p values based on two-sided x
2 tests (continuous variables)
or Fisher exact tests (categorical variables) were calculated for all
possible predictive factors. For the identification of predictors of
ACR50 and good responses according to EULAR criteria, the
ensemble of all factors was investigated by logistic regression
with backward elimination (selection level was 5%). The
predictive value of the final model was assessed by calculating
the area under the receiver operating characteristic (ROC) curve.
For a >3-grade improvement in PGA and a >50% improvement
in NAPSI score, we separately investigated only the predictors
because datasets for the complete ensemble of possible
predictors were missing in .20% of patients with skin and nail
lesions; thus, a selection bias could not be excluded. All values
presented are mean (SD) unless otherwise noted.
RESULTS
Patient disposition, withdrawals and adalimumab treatment
duration
Of the 442 patients enrolled, 94% completed week 12 and 39%
continued beyond week 12. During the complete treatment
period, 6 (1.4%) patients withdrew because of unsatisfactory
therapeutic response and 26 (5.9%) patients withdrew because
of adverse events. Other reasons (withdrawal of consent,
protocol violation, loss to follow-up, or other) are not shown.
The mean adalimumab treatment duration was 103 days
(median, 85 days).
Patient characteristics at baseline
Patient baseline characteristics are shown in table 1. All patients
had psoriatic symptoms at baseline and/or a history of psoriasis.
Plaque psoriasis (defined as PGA not ‘‘clear’’) was documented
in 366 (82.8%) patients, encompassing 206 patients with PGA
greater than ‘‘mild’’ (‘‘mild to moderate’’ in 59 patients,
‘‘moderate’’ in 82 patients, ‘‘moderate to severe’’ in 46 patients
and ‘‘severe’’ in 19 patients). Psoriatic nail dystrophy (NAPSI .
0) was reported for 259 (59.3%) patients, including 164 patients
with a mean NAPSI of >10.
Effectiveness of adalimumab treatment
ACR, EULAR and modified PsARC response rates at week 12,
percentages of patients with PGA ‘‘clear’’ or ‘‘almost clear’’ and
changes in target lesion and NAPSI score are shown in figs 1–4.
The mean number of tender and swollen joints and mean
DAS28, HAQ-DI and DLQI scores were reduced by 61%, 73%,
45%, 47% and 41%, respectively, from baseline to week 12. The
supplementary material provides a detailed summary of
effectiveness measures.
Identification of predictors of a good clinical response
Predictors of good clinical response for PsA at week 12
The logistic regression with backward elimination revealed that
a lower HAQ-DI score, male sex, no systemic therapy with
glucocorticoids and a greater patient’s assessment of pain were
strongly associated with achievement of ACR50 and good
response according to EULAR criteria (table 2). The area under
the ROC curve was 0.72 for the final models of predictor
identification for ACR50 and good response according to
EULAR criteria. Results for all individual predictors analysed
are shown in the supplementary material.
Predictors of good clinical response for psoriasis at week 12
Improvement of >3 grades in PGA was experienced by 81 (42%,
13 missing) of the 206 patients with a baseline PGA greater than
Table 1 Baseline characteristics of patients with psoriatic arthritis
(PsA) at baseline
All patients (n=442)
Female, n (%) 221 (50.0)
Median (SD) age, years 47.8 (11.5)
Mean (SD) PsA duration, years 10.6 (8.2)
Mean (SD) psoriasis duration, years 19.4 (12.9)
Rheumatoid factor positive, n (%) 51 (11.6)
Anti-CCP antibody positive, n (%) 28 (6.3)
HLA-B27 positive, n (%) 102 (23.3)
Dactylitis, n (%) 131 (29.7)
Enthesitis, n (%) 154 (34.9)
Swollen joint count (0–66), median (quartile 1, quartile 3) 8 (5, 13)
Mean (SD) DAS28 4.93 (1.15)
Prior anti-TNF therapy, n (%) 66 (14.9)
Ongoing DMARD therapy, n (%) 301 (68.1)
Ongoing systemic glucocorticoid therapy*, n (%) 128 (28.9)
*Maximum, prednisone equivalent 10 mg/day.
CCP, cyclic citrullinated peptide; DAS28, 28-joint Disease Activity Score; DMARD,
disease-modifying antirheumatic drug; HLA, human leukocyte antigen; TNF, tumour
necrosis factor.
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predictors, only a PGA greater than ‘‘moderate’’ (crude OR
2.27, 95% CI 1.22 to 4.24; p=0.011) and a greater PaGA of
disease activity (crude OR 1.02, 95% CI 1.00 to 1.03; p=0.043)
were associated with improvement in PGA by >3 grades.
Predictorsofgoodclinicalresponseforpsoriaticnaildisorderatweek12
Improvement in NAPSI score by >50% was experienced by 84
(54.2%, 9 missing) of 164 patients with a baseline NAPSI score
>10. In the analysis of individual possible predictors, only lower
CRP concentration was associated with >50% improvement in
NAPSI score (crude OR 0.79, 95% CI 0.65 to 0.96; p=0.019).
Safety
There were 21 serious adverse events, including 4 infections,
documented for 18 (4.1%) patients during adalimumab treat-
ment and a 70-day follow-up. Detailed data are summarised in
the supplementary material.
DISCUSSION
The clinical manifestations of PsA in this large study cohort are
consistent with the typical pattern of PsA symptoms reported
in the literature, and the patient characteristics are representa-
tive of those considered eligible for anti-TNF therapy.
121 31 4
After 12 weeks of adalimumab therapy, 74%, 51% and 32% of
the patients experienced ACR20, 50 and 70 responses, respec-
tively. These rates are somewhat greater than those found in
randomised controlled trials (RCTs) with adalimumab or other
TNF antagonists, which may be because the calculated rates in
our study were based on observed values.
15–17 Moderate and
good responses according to EULAR criteria were achieved by
87% and 61% of patients, respectively, which is similar to the
reported rates in pooled data from two RCTs of other anti-TNF
agents (etanercept and infliximab).
12 The safety profile of
adalimumab in this 12-week study was consistent with results
from RCTs of adalimumab for PsA.
17 18
Improvement in psoriasis was clinically relevant, with
doubling of the baseline percentage of patients with PGA
‘‘clear’’ or ‘‘almost clear’’ skin at week 12 and a median
reduction of the target lesion total plaque score by 67%. The
results appear to be within the extent of improvement under
anti-TNF therapy when other psoriasis assessment tools were
used.
15–17
This is the first study that has investigated the effect of
adalimumab on nail psoriasis. After the relatively short
Figure 1 Percentages of patients
achieving American College of
Rheumatology 20%, 50% and 70%
response criteria (ACR20/50/70),
moderate and good European League
Against Rheumatism (EULAR) criteria
responses and the modified psoriatic
arthritis response criteria (mPsARC) at
week 12 (n=414). Data are from
observed cases.
Figure 2 Percentages of patients
achieving Physician Global Assessment of
psoriasis (PGA) ‘‘clear’’ or ‘‘almost clear’’
up to week 20. All patients are included,
data are from observed cases.
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score was 57%. Clearance of psoriasis of the nails was increasing
in those patients who continued adalimumab up to week 20.
These results are comparable to those reported for infliximab
treatment of nail disorder in patients with PsA.
19
Our results show that good clinical responses in the various
manifestations of PsA (ie, joints, skin and nails) are influenced
by various predictive factors. Achievement of ACR50 and a good
response according to EULAR criteria was more likely when
patients had a lower HAQ-DI score and greater pain. Men had a
twofold greater chance of achieving ACR50 and good response
according to EULAR criteria compared with women. Systemic
glucocorticoid therapy, which is generally not recommended for
PsA, decreased the chance of a good response.
1 The chance of
achieving ACR50 was also better for patients with greater CRP
concentrations and polyarticular PsA, whereas large joint
involvement decreased the chance of a good response according
to EULAR criteria. These findings are consistent with a
predictor analysis in 69 infliximab-treated patients.
20
Because several of the potential predictors are components of
the response criteria, one might expect that greater baseline
values would be associated with greater response. With respect
to CRP, for example, it is interesting that lower baseline CRP
concentrations predict an ACR50 response for patients with
rheumatoid arthritis,
21 which is in contrast to our findings for
patients with PsA. For Bath Ankylosing Spondylitis Disease
Activity Index 50% response (BASDAI 50), which does not
include CRP, greater baseline CRP concentration predicts a
BASDAI 50 response for patients with ankylosing spondylitis.
22
Thus, CRP appears to be a true biological predictor, and other
components of the response criteria may likewise have
independent predictive value. Finally, prior use of at least two
DMARDs and concomitant treatment with SSZ were asso-
ciated with the achievement of a good response according to
EULAR criteria. Of note, few patients (10.4%) were concomi-
tantly treated with SSZ (either alone or combined with other
DMARDs).
The endpoints of a >3-grade improvement in PGA and a
>50% improvement in NAPSI score were arbitrarily selected to
correspond with ACR50. We found an association between
PaGA of disease activity and >3-grade improvement in PGA.
Although greater PGA severity at baseline was associated with
Figure 3 Improvement in median target
lesion total plaque score up to week 20
for patients with target lesion >2c mi n
greatest diameter at baseline. Data are
from observed cases. *Quartile 1 to
quartile 3. **Median change (means not
presented because of skewed
distributions).
Figure 4 Improvement in median Nail
Psoriasis Severity Index (NAPSI) score at
weeks 12 and 20 for patients with nail
dystrophy (NAPSI .0) at baseline. Data
are from observed cases. *Quartile 1 to
quartile 3. **Median change (means not
presented because of skewed
distributions).
Extended report
Ann Rheum Dis 2010;69:394–399. doi:10.1136/ard.2009.111856 397greater improvement in PGA, this finding appears to be
intrinsically caused by the method and should not be considered
a real predictor. A >50% improvement in NAPSI score was more
likely for patients with lower CRP concentrations at baseline,
which is opposite to the impact of CRP concentration on
achievement of an ACR50 response.
In conclusion, patients with long-term active PsA experienced
clinically important improvement in arthritis, psoriasis and
psoriatic nail disorder. Low impairment of physical function
(lower HAQ-DI score), greater pain, greater CRP concentration,
polyarthritis without inflammation of large joints, prior
treatment with .2 DMARDs, current treatment with SSZ
but not glucocorticoids and male sex were factors that increased
the chance of achieving substantial clinical improvements.
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